Summary & Overview
CPT 51720: Bladder Instillation of Anticarcinogenic Agent
CPT code 51720 represents the bladder instillation of an anticarcinogenic agent, a procedure integral to the management of bladder cancer and related urological conditions. This code is widely used in outpatient settings, reflecting its importance in ongoing cancer care and disease management. Nationally, the procedure is covered by major payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, ensuring broad access for patients across diverse insurance plans.
This publication provides a comprehensive overview of CPT 51720, including clinical context, payer coverage, and relevant policy updates. Readers will gain insight into the procedure's role in urology, typical sites of service, and its relationship to other bladder-related CPT codes. The summary also highlights common billing modifiers and associated provider taxonomies, offering clarity for stakeholders navigating reimbursement and compliance. Benchmarks and trends in utilization are discussed, equipping healthcare professionals, administrators, and policy analysts with the information needed to understand the national landscape for bladder instillation procedures.
CPT Code Overview
CPT 51720 describes the bladder instillation of an anticarcinogenic agent, including retention time. This procedure is commonly performed in the field of urology and is typically provided in an outpatient setting, such as a physician's office. The instillation is used as part of treatment protocols for patients with bladder conditions requiring targeted therapy with anticarcinogenic agents.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an individual diagnosed with bladder cancer or other bladder-related conditions who requires treatment with an anticarcinogenic agent. The procedure is performed in an outpatient setting, such as a urology office. The workflow includes the patient presenting with symptoms or a diagnosis (e.g., hematuria, bladder-neck obstruction, acute cystitis), followed by the urologist instilling an anticarcinogenic agent into the bladder via catheterization. The agent is retained for a specified period to maximize therapeutic effect. This procedure is commonly performed by urology specialists and may be part of ongoing management for bladder neoplasms or other relevant conditions.
Coding Specifications
-
Modifiers:
- Modifier
26: Used to indicate the professional component of the service, typically when the physician provides only the interpretation and reporting. - Modifier
TC: Used for the technical component, indicating the use of equipment, supplies, and technical staff. - Modifier
59: Used to denote a distinct procedural service, when the procedure is separate from other services performed on the same day.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Description |
|---|---|
208800000X | Urology Physician |
2088P0231X | Pediatric Urology Physician |
2088F0040X | Female Pelvic Medicine and Reconstructive Surgery Physician |
These taxonomies represent providers specializing in urology, pediatric urology, and female pelvic medicine and reconstructive surgery.
Related Diagnoses
-
C67.9- Malignant neoplasm of bladder, unspecified- Indicates bladder cancer, which is a primary indication for instillation of anticarcinogenic agents.
-
D49.4- Neoplasm of unspecified behavior of bladder- Used when the nature of the bladder neoplasm is unclear; may warrant preventive or therapeutic instillation.
-
N32.0- Bladder-neck obstruction- Obstruction may necessitate instillation procedures for management or symptom relief.
-
R31.9- Hematuria, unspecified- Presence of blood in urine can be a symptom of bladder pathology; instillation may be part of diagnostic or therapeutic approach.
-
N30.00- Acute cystitis without hematuria- Acute inflammation of the bladder; instillation may be used for treatment or symptom management.
Related CPT Codes
| CPT Code | Description | Clinical Relationship to 51720 |
|---|---|---|
51700 | Bladder irrigation, simple, lavage and/or instillation | May be used for simpler bladder instillation procedures; alternative to 51720 when anticarcinogenic agent is not used. |
51701 | Insertion of non-indwelling bladder catheter | Often performed prior to instillation; preparatory step for 51720. |
51702 | Insertion of temporary indwelling bladder catheter | May be used if retention of agent is required; preparatory or adjunct to 51720. |
51703 | Insertion of temporary indwelling bladder catheter; complicated | Used in cases where catheterization is complex; may precede 51720. |
51725 | Simple cystometrogram (CMG) | Diagnostic procedure; may be performed in conjunction with 51720 for bladder function assessment. |
51726 | Complex cystometrogram (CMG) with urethral pressure profile studies | Advanced diagnostic; may be used alongside 51720 in complex cases. |
Codes 51701, 51702, and 51703 are commonly used as preparatory steps for bladder instillation. Codes 51725 and 51726 are diagnostic and may be performed in the same clinical workflow if bladder function assessment is needed.
National Reimbursement Benchmarks
Medicare's national mean rate for CPT code 51720 is $94.95, while the BUCA (average commercial) mean rate is higher at $106.88. Commercial payers such as UnitedHealth Group and Cigna report even higher mean rates, at $136.22 and $130.14 respectively, compared to Blue Cross Blue Shield at $108.70 and Aetna at $83.74.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Medicare exhibits the tightest range ($98.00 - $89.00 = $9.00), indicating less variability in rates. In contrast, UnitedHealth Group shows the widest dispersion ($159.67 - $89.18 = $70.49), followed by Cigna ($156.00 - $87.00 = $69.00). This suggests that commercial payers have greater variability in reimbursement rates for this code.
The table and chart below present the full breakdown of national benchmarks for each payer, including mean rates and percentile values.
State Benchmarks
State: AK1 / 50
Alaska Benchmarks
Alaska's reimbursement rates for CPT code 51720 show substantial variation across payers, with the highest mean rate from Aetna at $262.13 and the lowest from Medicare at $91.96. The rate spread, calculated as the difference between the 75th and 25th percentiles, is most pronounced for Blue Cross Blue Shield ($60.26) and Cigna ($94.00), indicating greater variability in commercial payer rates. Aetna and UnitedHealth Group display minimal spread, suggesting more standardized rates within those payers.
Compared to national averages, Alaska's commercial payers consistently reimburse at much higher rates, with Aetna's mean rate more than triple the national mean. The table and chart below present the full breakdown of payer-specific rates, highlighting the significant differences in reimbursement across the state.
Key Insights for Alaska
- Aetna is the highest paying payer in Alaska for CPT 51720, with a mean rate of $262.13, while Medicare is the lowest at $91.96.
- All commercial payers in Alaska reimburse at rates significantly above their respective national averages, with Aetna's mean rate more than triple the national mean.
- The rate spread is widest for Aetna (P75-P25 = $0, due to uniformity), but Blue Cross Blue Shield and Cigna show meaningful variability, indicating less standardized reimbursement.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.